Part-time Versus Full-time Spectacles for Myopia Control (ParMA Study)

Sponsor
Aristotle University Of Thessaloniki (Other)
Overall Status
Completed
CT.gov ID
NCT04854447
Collaborator
State Scholarships Foundation (Other)
30
1
2
24.3
1.2

Study Details

Study Description

Brief Summary

The purpose is to assess the effect of part-time compared to full-time spectacle use in juvenile myopia control.

Condition or Disease Intervention/Treatment Phase
  • Device: Single-Vision Spectacles
N/A

Detailed Description

A prospective, randomized, controlled clinical trial was designed for assessing the effect of single-vision spectacles on myopic progression. 30 myopic subjects, aged 6-16 years old, with a spherical equivalent refraction between -0.50D and -6.00D, were recruited. A random number table was used to allocate participants into either a) part-time use of single-vision spectacles, or b) full-time use of single-vision spectacles. Part-time use was for 4-6 hours a day, 7 days a week for a year. Clinical assessment included follow-up at 6 months and at 12 months upon allocation. The primary outcomes were a) change in spherical equivalent refraction (SER) measured by cycloplegic autorefraction, and b) change in axial eye length (AL). The secondary outcomes were a) change in choroidal thickness (ChT), and b) assessment of the subjective tolerance.

Study Design

Study Type:
Interventional
Actual Enrollment :
30 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Part-time Versus Full-time Spectacles for Myopia Control (ParMA Study)
Actual Study Start Date :
Nov 15, 2019
Actual Primary Completion Date :
Jun 28, 2021
Actual Study Completion Date :
Nov 25, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Study Group

Part-time myopia correction with single-vision spectacles

Device: Single-Vision Spectacles
Spectacle correction for myopia treatment

Active Comparator: Control Group

Full-time myopia correction with single-vision spectacles

Device: Single-Vision Spectacles
Spectacle correction for myopia treatment

Outcome Measures

Primary Outcome Measures

  1. Change in spherical equivalent refractive error (SER), measured using cycloplegic autorefraction. [Baseline to 6-months, and baseline to 12-months.]

  2. Change in axial length (AL). [Baseline to 6-months, and baseline to 12-months.]

Secondary Outcome Measures

  1. Change in choroidal thickness (ChT). [Baseline to 6-months, and baseline to 12-months.]

  2. Subjective tolerance, as assessed using a standardized questionnaire created for the purpose of this study. [Baseline to 12-months.]

    This questionnaire is formed by the researchers participating in this study and is aimed at providing a qualitative assessment of the subjective tolerance of included children wearing spectacles. It incorporates 6 questions and is not based on a scale.

Eligibility Criteria

Criteria

Ages Eligible for Study:
4 Years to 16 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age 4 to 16 years old at the time of enrollment.

  • Best-corrected visual acuity (BCVA) LogMAR 0.1 or better, in each eye.

  • Cycloplegic Autorefraction: Myopia, SER between -0.50D and -6.00D, in each eye. Astigmatism less than or equal to 1.50D, in each eye. Anisometropia less than or equal to 1.50D between the two eyes.

  • Absence of any ocular or systemic condition that could influence refractive development, other than myopia.

  • Eagerness to participate in this study and receive myopia treatment in a randomized fashion. Availability for at least 1-year follow-up. Subject parent's or guardian's understanding of the protocol and acceptance to participate, providing a signed consent on behalf of the subject.

Exclusion Criteria:
  • Presence of strabismus.

  • Presence of amblyopia.

  • Prematurity (gestational age less than 37 weeks).

  • Presence of an ocular condition affecting refraction (ie. cataract, dislocated lens).

  • Presence of a systemic condition affecting refraction (ie. Down syndrome, Marfan syndrome).

  • Allergy to cyclopentolate. Severe ocular or systemic allergies.

Contacts and Locations

Locations

Site City State Country Postal Code
1 "Papageorgiou" General Hospital ThessalonĂ­ki Greece 56429

Sponsors and Collaborators

  • Aristotle University Of Thessaloniki
  • State Scholarships Foundation

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Asimina Mataftsi, Associate Professor in Ophthalmology, Paediatric Ophthalmology and Strabismus, Aristotle University Of Thessaloniki
ClinicalTrials.gov Identifier:
NCT04854447
Other Study ID Numbers:
  • 2.68/27-02-2019
First Posted:
Apr 22, 2021
Last Update Posted:
Dec 22, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Asimina Mataftsi, Associate Professor in Ophthalmology, Paediatric Ophthalmology and Strabismus, Aristotle University Of Thessaloniki
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 22, 2021